CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05432791
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:00.408600+00:00
Published At: 2026-04-08T00:00:00+00:00
Record Updated At: 2026-04-08
Results Posted At: 2026-04-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Locally Advanced Uterine Corpus Leiomyosarcoma", "Metastatic Uterine Corpus Leiomyosarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Uterine Corpus Leiomyosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-08"
protocolSection.identificationModule.nctId: "NCT05432791"
protocolSection.identificationModule.officialTitle: "A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator\u0027s Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-04-08"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.